Evercore ISI Group Maintains Outperform on Insmed, Lowers Price Target to $160
Benzinga Newsdesk 4 months ago
Analyst RatingsNewsPrice Target
Evercore ISI Group analyst Josh Schimmer maintains Insmed (NASDAQ:INSM) with a Outperform and lowers the price target from $162 to $160.
Evercore ISI Group analyst Josh Schimmer maintains Insmed (NASDAQ:INSM) with a Outperform and lowers the price target from $162 to $160.